Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC news

   Watch this stock
Showing stories 1 - 10 of about 106   

Articles published

SHP 3,480.00 -18.00 (-0.51%)
price chart
Shire PLC (SHPG) Hits New 52-Week Low Following Analyst Downgrade
Shire PLC logo Shares of Shire PLC (NASDAQ:SHPG) reached a new 52-week low during trading on Tuesday after Susquehanna lowered their price target on the stock from $280.00 to $220.00, MarketBeat.
Shire PLC (ADR) (NASDAQ:SHPG) Had Its Price Target Lowered by 21.43 % at ...
Key Stocks of the Day: Shire plc (NASDAQ:SHPG)  The News Journal
Shire PLC (SHP) Stock Rating Reaffirmed by JPMorgan Chase & Co.
Shire PLC (LON:SHP)'s stock had its “overweight” rating reaffirmed by research analysts at JPMorgan Chase & Co.
UBS Analyst Reaffirmed GBX 5200.00 Price Target on Shire Plc (LON:SHP) stock ...
Shire PLC (SHP) Given Overweight Rating at JPMorgan Chase & Co.  Intercooler Financial
Shire plc (SHPG) to Acquire Baxalta (BXLT) in ~$32B Deal
Shire plc (NASDAQ: SHPG) and Baxalta Incorporated (NYSE: BXLT) today announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta.
Drugmaker Shire to buy Baxalta for $32 billion after six-month pursuit  Reuters
Shire PLC Spends $32 Billion on Baxalta Inc. -- An Arbitrage Opportunity?  Motley Fool
Why Now Is The Time To Buy HSBC Holdings plc, Shire Plc And Rolls-Royce ...
Long-term investors should be viewing the market sell-off since the New Year as an opportunity to snap up shares of well-run companies that have been unfairly dented by broader market panic.
Shire PLC (SHP) Earns Buy Rating from Jefferies Group  Intercooler Financial
Is Now The Time To Buy Shire PLC, SkyePharma PLC And Indivior PLC?
Is there value in small and mid-sized pharmaceutical companies? Three popular choices with solid profits are Shire (LSE: SHP), SkyePharma (LSE: SKP) and Indivior (LSE: INDV).
Why I'd Buy GlaxoSmithKline plc Over Smith & Nephew plc And Shire PLC
Shares in GlaxoSmithKline (LSE: GSK) were given a boost this week when it reported better-than-expected quarterly results. Furthermore, it announced that its transformation programme is on track and that the company in on target to deliver �3bn in ...
Shire PLC (SHPG) Price Target Cut to $220.00 by Analysts at Susquehanna
Shire PLC logo Shire PLC (NASDAQ:SHPG) had its target price decreased by Susquehanna from $280.00 to $220.00 in a research note issued to investors on Monday, StockTargetPrices.
Shire plc (NASDAQ:SHPG) Analyst Ratings and Target Update  Uptick Analyst
Price Target Update On Shire Plc (NASDAQ:SHPG)  Risers & Fallers
Moody's assigns Baa3 issuer rating to Shire plc; stable outlook
Headquartered in Dublin, Ireland and domiciled in Jersey (Channel Islands), Shire plc ("Shire") is a global biopharmaceutical company with expertise in rare diseases, neuroscience and gastroenterology.
S&P Starts Shire plc (SHPG) at 'BBB-'; Outlook Stable
Shire plc Assigned Investment Grade Credit Ratings by Moody's and S&P  PR Newswire (press release)
Intercept Pharmaceuticals Inc: Shire Busy in Baxalta Acquisition, AstraZeneca ...
The biopharmaceutical company has been in light in the context of possible merger rumors, with rival Shire PLC mentioned as a potential suitor.
Expert View: Finance, tax & strategy in the Shire-Baxalta merger  The Pharma Letter (registration)
Are Healthcare Superstars Shire PLC, AstraZeneca plc and GlaxoSmithKline plc ...
Shire (LSE: SHP) has outperformed the market by a vast amount in the last few years but recently the shares have fallen away from highs.